"Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine" . "Ko\u0159\u00EDnkov\u00E1, Gabriela" . . . "3757-3764" . "Hajd\u00FAch, Mari\u00E1n" . . . . "Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine"@en . "Krupi\u010Dkov\u00E1, Stanislava" . "DE - Spolkov\u00E1 republika N\u011Bmecko" . "8"^^ . "0173-0835" . "G38" . . "P(LN00A033), P(MO66020398130), Z(MSM 153100008)" . "[40C5A553A5B0]" . "2"^^ . "Proteomov\u00FDp\u0159\u00EDstup ke klasifikaci biochemick\u00E9 podstaty proti n\u00E1dorov\u00E9 aktivit\u011B syntetick\u00E9ho boheminu od olomoucinu odvozen\u00E9 cyklin dependentn\u00ED kin\u00E1zy"@cs . . "Gouldsworthy, Al" . "RIV/60162694:G38__/00:00000359!RIV/2005/MO0/G38005/N" . "In eukaryotic cells the activity of cyclin dependent kinases (CDKs) is precisely regulated. This regulation maintains a proper coordination of the individual steps in cell division cycle. Due to the fact that the family of natural CDK inhibitors (CDKIs) belong to the most frequently mutated proteins in cancer cells, molecules that could mimic their biological activities are attractive candidates for anti-cancer treatment. The aim of this study was use 2-DE coupled with multivariate principal component analysis (PCA) to characterize the quantitative changes in the protein composition of the CEM T-lymphoblastic leukemia cell line after treatment with bohemine (BOH), a synthetic olomoucin derived CDKI. Cell classification, reflecting protein patterns, clearly distinguished two main groups: one group consists of 9, 12 and 24 - hour treated BOH cells while the second is represented by the 0 and 24 - hour control untreated cells and the 6- hour BOH exposed CEM lymphoblasts. Discriminant protein spots di" . . "Proteomov\u00FDp\u0159\u00EDstup ke klasifikaci biochemick\u00E9 podstaty proti n\u00E1dorov\u00E9 aktivit\u011B syntetick\u00E9ho boheminu od olomoucinu odvozen\u00E9 cyklin dependentn\u00ED kin\u00E1zy"@cs . "Zhelev, Ni" . . . "8"^^ . "723852" . . "Electrophoresis" . . "In eukaryotic cells the activity of cyclin dependent kinases (CDKs) is precisely regulated. This regulation maintains a proper coordination of the individual steps in cell division cycle. Due to the fact that the family of natural CDK inhibitors (CDKIs) belong to the most frequently mutated proteins in cancer cells, molecules that could mimic their biological activities are attractive candidates for anti-cancer treatment. The aim of this study was use 2-DE coupled with multivariate principal component analysis (PCA) to characterize the quantitative changes in the protein composition of the CEM T-lymphoblastic leukemia cell line after treatment with bohemine (BOH), a synthetic olomoucin derived CDKI. Cell classification, reflecting protein patterns, clearly distinguished two main groups: one group consists of 9, 12 and 24 - hour treated BOH cells while the second is represented by the 0 and 24 - hour control untreated cells and the 6- hour BOH exposed CEM lymphoblasts. Discriminant protein spots di"@en . "Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine"@en . . . "17" . "RIV/60162694:G38__/00:00000359" . . . "Proteomov\u00FDp\u0159\u00EDstup ke klasifikaci biochemick\u00E9 podstaty proti n\u00E1dorov\u00E9 aktivit\u011B syntetick\u00E9ho boheminu od olomoucinu odvozen\u00E9 cyklin dependentn\u00ED kin\u00E1zy"@cs . "Halada, Petr" . . . . "anticancer activity;olomoucine;kinase inhibitor;bohemine"@en . "Kov\u00E1\u0159ov\u00E1, Hana" . . "Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine" . "21" . "Strnad, Miroslav" .